Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 9 studies | 23% ± 6% | |
endothelial cell | 9 studies | 21% ± 6% | |
adipocyte | 9 studies | 36% ± 12% | |
pericyte | 9 studies | 30% ± 14% | |
type I pneumocyte | 8 studies | 30% ± 9% | |
astrocyte | 6 studies | 27% ± 11% | |
fibroblast | 5 studies | 20% ± 4% | |
B cell | 4 studies | 23% ± 1% | |
glutamatergic neuron | 4 studies | 34% ± 17% | |
epithelial cell | 3 studies | 21% ± 4% | |
retinal pigment epithelial cell | 3 studies | 18% ± 3% | |
capillary endothelial cell | 3 studies | 25% ± 6% | |
endothelial cell of artery | 3 studies | 19% ± 3% | |
naive B cell | 3 studies | 22% ± 2% | |
oligodendrocyte precursor cell | 3 studies | 21% ± 2% | |
Schwann cell | 3 studies | 39% ± 22% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 29% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 3907.50 | 180 / 180 | 100% | 21.77 | 430 / 430 |
adrenal gland | 100% | 6640.24 | 258 / 258 | 99% | 19.29 | 228 / 230 |
breast | 100% | 7515.91 | 459 / 459 | 96% | 10.47 | 1071 / 1118 |
lung | 99% | 5020.73 | 575 / 578 | 96% | 12.10 | 1108 / 1155 |
brain | 94% | 2625.63 | 2482 / 2642 | 100% | 25.42 | 705 / 705 |
thymus | 95% | 2120.67 | 623 / 653 | 96% | 9.98 | 581 / 605 |
prostate | 92% | 2465.76 | 225 / 245 | 99% | 7.73 | 495 / 502 |
uterus | 99% | 3639.75 | 168 / 170 | 91% | 15.21 | 419 / 459 |
kidney | 93% | 2762.72 | 83 / 89 | 95% | 16.57 | 853 / 901 |
bladder | 90% | 3825.67 | 19 / 21 | 91% | 13.38 | 461 / 504 |
intestine | 87% | 2664.23 | 840 / 966 | 88% | 8.07 | 464 / 527 |
pancreas | 70% | 1180.41 | 230 / 328 | 97% | 11.79 | 172 / 178 |
skin | 65% | 2316.48 | 1180 / 1809 | 100% | 28.06 | 470 / 472 |
esophagus | 73% | 2644.94 | 1058 / 1445 | 91% | 10.53 | 166 / 183 |
stomach | 68% | 1749.81 | 243 / 359 | 91% | 9.15 | 261 / 286 |
liver | 60% | 933.74 | 136 / 226 | 97% | 12.08 | 393 / 406 |
adipose | 100% | 10387.34 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 26.87 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 36.91 | 29 / 29 |
blood vessel | 100% | 10134.21 | 1334 / 1335 | 0% | 0 | 0 / 0 |
spleen | 99% | 2571.56 | 239 / 241 | 0% | 0 | 0 / 0 |
heart | 99% | 4615.99 | 853 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 9.23 | 41 / 45 |
muscle | 89% | 2812.76 | 717 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 5% | 67.76 | 49 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006636 | Biological process | unsaturated fatty acid biosynthetic process |
GO_0006629 | Biological process | lipid metabolic process |
GO_0006665 | Biological process | sphingolipid metabolic process |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0016717 | Molecular function | oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water |
GO_0005515 | Molecular function | protein binding |
GO_0003674 | Molecular function | molecular_function |
Gene name | FADS3 |
Protein name | Fatty acid desaturase 3 Fatty acid desaturase 3 (FADS3) (EC 1.14.19.-) (Delta(13) fatty acid desaturase) (Delta(13) desaturase) |
Synonyms | CYB5RP |
Description | FUNCTION: Mammals have different sphingoid bases that differ in their length and/or pattern of desaturation and hydroxyl groups. The predominant sphingoid base that comprises mammalian ceramides is sphing-4-enine (sphingosine or SPH) which has a trans (E) desaturation at carbon 4 . FADS3 is a desaturase that introduces a cis (Z) double bond between carbon 14 and carbon 15 of the sphingoid base (also known as long chain base, LCB), producing LCBs such as sphinga-4,14-dienine (SPD, d18:2(4E,14Z)) from SPH . Prefers SPH-containing ceramides (N-acylsphing-4-enines) as substrates . Capable of metabolizing also the SPH in its free form . SPD ceramides occur widely in mammalian tissues and cells . Due to their unusual structure containing a cis double bond, SPD ceramides may have an opposite, negative role in lipid microdomain formation relative to conventional ceramides . Could be involved in the detoxification of 1-deoxy sphingolipids, by desaturating the cytotoxic 1-deoxysphinganine (1-deoxySA, m18:0), produced under pathological conditions, to 1-deoxysphingenine (1-deoxysphingosine, 1-deoxySO, m18:1) (Probable). Although prefers SPH-containing ceramides (N-acylsphing-4-enines) as substrates, it also exhibits activity toward dihydrosphingosine-containing CERs (N-acylsphinganines) and produces 14Z-SPH-containing sphingolipids,which can be found in patients with DEGS1 mutations . Its desaturase mechanism involves an electron transfer facilitated by cytochrome b5 . FADS3 also acts as a methyl-end fatty acyl coenzyme A (CoA) desaturase that introduces a cis double bond between the preexisting double bond and the terminal methyl group of the fatty acyl chain (By similarity). Desaturates (11E)-octadecenoate (trans-vaccenoate, the predominant trans fatty acid in human milk) at carbon 13 to generate (11E,13Z)-octadecadienoate (also known as conjugated linoleic acid 11E,13Z-CLA) (By similarity). . |
Accessions | ENST00000525094.5 ENST00000531956.5 E9PKP8 ENST00000534223.5 Q9Y5Q0 ENST00000278829.7 H0YED5 E9PQC2 ENST00000527379.5 E9PPZ4 ENST00000527697.5 E9PS00 ENST00000525588.5 H0YCN1 |